(NASDAQ: ABEO) Abeona Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Abeona Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast ABEO's revenue for 2025 to be $2,184,991,586, with the lowest ABEO revenue forecast at $504,751,499, and the highest ABEO revenue forecast at $8,438,086,120. On average, 4 Wall Street analysts forecast ABEO's revenue for 2026 to be $3,644,160,223, with the lowest ABEO revenue forecast at $2,766,426,486, and the highest ABEO revenue forecast at $4,467,050,768.
In 2027, ABEO is forecast to generate $5,699,615,102 in revenue, with the lowest revenue forecast at $4,610,710,810 and the highest revenue forecast at $6,887,431,274.